Kanamycin
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Short-term treatment of infections caused by E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species.
- Note: other aminoglycosides including gentamicin, tobramycin, and/or amikacin are preferred in this setting.
- Staphylococcal infections (not drug of choice)
- Hepatic encephalopathy (oral formulation, no longer available in the U.S.)
- Bowel decontamination (oral formulation, no longer available in the U.S.)
NON-FDA APPROVED USES
- Treatment of multi-drug resistant Mycobacterium tuberculosis (second line)
- Non-tubercular mycobacterial (NTM) infections
- Gonorrhea
- Urinary tract infections
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Short-term treatment of infections caused by E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species.
- Note: other aminoglycosides including gentamicin, tobramycin, and/or amikacin are preferred in this setting.
- Staphylococcal infections (not drug of choice)
- Hepatic encephalopathy (oral formulation, no longer available in the U.S.)
- Bowel decontamination (oral formulation, no longer available in the U.S.)
NON-FDA APPROVED USES
- Treatment of multi-drug resistant Mycobacterium tuberculosis (second line)
- Non-tubercular mycobacterial (NTM) infections
- Gonorrhea
- Urinary tract infections
There's more to see -- the rest of this entry is available only to subscribers.